We are studying Asciminib for patients with Chronic Myeloid Leukemia who have the T315I mutation and have not responded to ponatinib. The trial aims to see how well it works and how safe it is.
Health conditions and diseases that the clinical trial is designed to study and treat.
Chronic Myeloid Leukemia (CML) is a type of cancer that starts in the blood-forming cells of the bone marrow and leads to the overproduction of myeloid cells. It can be associated with specific mutations, such as the T315I mutation, which can affect treatment options.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.